Ask about this productRelated genes to: Ccna2 antibody
- Gene:
- CCNA2 NIH gene
- Name:
- cyclin A2
- Previous symbol:
- CCNA, CCN1
- Synonyms:
- -
- Chromosome:
- 4q27
- Locus Type:
- gene with protein product
- Date approved:
- 1990-04-09
- Date modifiied:
- 2015-08-28
Related products to: Ccna2 antibody
Related articles to: Ccna2 antibody
- Sinonasal inverted papilloma is a locally aggressive epithelial lesion with a relatively high recurrence rate, yet the molecular basis of its proliferative behaviour remains incompletely understood. This study investigated the clinical relevance of secreted phosphoprotein 1 in sinonasal inverted papilloma and its association with epithelial cell proliferation and related signalling pathways. - Source: PubMed
Publication date: 2026/04/28
Tang WenruiWang LinYan XudongZhang JishengYu LonggangChen HanZheng ChungeDong ZihuiZheng QianyouHan LinJiang Yan - Polyethylene terephthalate (PET), one of the most widely used synthetic polymers globally, has emerged as a potential environmental risk factor for human health. However, the molecular mechanisms linking PET exposure to hepatocellular carcinoma (HCC) remain poorly understood. - Source: PubMed
Publication date: 2026/04/22
Chen PengLiu XinYuan DongmeiZheng LanDu YuminGong DacaiWei XingWang DanXu GeGe Bin - Metabolic reprogramming and the formation of an immunosuppressive tumor microenvironment(TME) are hallmarks of osteosarcoma (OS). However, the metabolic characteristics of OS and its associated immune microenvironment remain largely unknown. - Source: PubMed
Publication date: 2026/05/06
Jiang BingjieZhu HaoranZhang Zhenxing - - Source: PubMed
Publication date: 2026/04/17
Xu ChuanqinAi Bo - The widely used chemotherapeutic drug cisplatin (CDDP) is an integral part of the preoperative chemotherapy protocol for high-grade osteosarcoma (OS). However, despite an aggressive treatment regimen, drug refractoriness is a major hindrance to successful therapy. We previously identified key transcriptomic alterations that support the survival of OS cells following CDDP exposure. In the present study, our analyses further demonstrate that CDDP treatment promotes an adaptive, ROS-dependent enrichment of the repressive histone mark H3K27me3 at the upstream promoter regions of growth-associated genes such as CCNA2, as well as at the promoter of LATS1, a negative regulator of Yes-Associated Protein (YAP). This enrichment contributes to the transcriptional repression of these genes and is associated with growth arrest; notably, quenching of reactive oxygen species with -acetyl cysteine (NAC) reversed this effect. Furthermore, reduced LATS1 expression was associated with increased nuclear localization of YAP. Importantly, pharmacological inhibition or genetic ablation of YAP attenuated the CDDP-induced accumulation of repressive marks. Mechanistically, YAP was found to colocalize and coimmunoprecipitate with EZH2, the catalytic member of the Polycomb Repressive Complex 2 (PRC2), suggesting a potential role for YAP in facilitating EZH2-mediated transcriptional repression. Consistent with these observations, inhibition of YAP or pharmacological reversal of the repressive chromatin state using a histone deacetylase (HDAC) inhibitor enhanced the sensitivity of the OS cells to low-dose CDDP treatment. Overall, the present study demonstrates an interplay among oxidative stress, epigenetics, and YAP in modulating OS cell fate post-CDDP exposure. - Source: PubMed
Publication date: 2026/04/14
Daiya AnkitaNayak ChinmayChowdhury RajdeepChowdhury ShibasishMukherjee Sudeshna